Buckwheat Sensitivity
Notably, Geiselhart et al. set out in 2017 to characterize concomitant sensitivities in patients allergic to buckwheat. They divided subjects selected by positive skin prick tests into a group sensitive to buckwheat without clinical signs and an allergic group, finding that patients with clinical symptoms presented with a distinct allergen recognition pattern. Specifically, the researchers noted that a new allergen, Fag e 4, which may cross react with latex, warranted addition to the allergen panel of buckwheat and that concomitant sensitization to legumin, Fag e 2 and Fag e 5 predicts buckwheat allergy.9Conclusion
Because it is a popular component in many diets around the world, especially Japan, Korea, Russia, and Poland, as well as other Asian and European countries, South Africa, Australia, and North America,4 it is reasonable to expect that we’ll see more research on buckwheat. For now, there are indications to suggest that more investigations are warranted to determine whether this botanical agent will have a meaningful role in the dermatologic armamentarium.
References
1. Li SQ et al. Crit Rev Food Sci Nutr. 2001 Sep;41(6):451-64.
2. Dattner AM. Dermatol Ther. 2003;16(2):106-13.
3. Hinneburg I et al. J Agric Food Chem. 2005 Jan 12;53(1):3-7.
4. van den Berg AJ et al. J Wound Care. 2008 Apr;17(4):172-4, 176-8.
5. Liu CL et al. J Agric Food Chem. 2008 Jan 9;56(1):173-8.
6. Zhou J et al. Food Chem Toxicol. 2012 Aug;50(8):2766-73.
7. Trommer H et al. J Pharm Pharm Sci. 2005 Sep 15;8(3):494-506.
8. Hinneburg I et al. Pharmazie. 2006 Mar;61(3):237-40.
9. Geiselhart S et al. Clin Exp Allergy. 2018 Feb;48(2):217-24.
Dr. Baumann is a private practice dermatologist, researcher, author, and entrepreneur who practices in Miami. She founded the Cosmetic Dermatology Center at the University of Miami in 1997. Dr. Baumann wrote two textbooks: “Cosmetic Dermatology: Principles and Practice” (New York: McGraw-Hill, 2002) and “Cosmeceuticals and Cosmetic Ingredients” (New York: McGraw-Hill, 2014); she also authored a New York Times Best Seller for consumers, “The Skin Type Solution” (New York: Bantam Dell, 2006). Dr. Baumann has received funding for advisory boards and/or clinical research trials from Allergan, Evolus, Galderma, and Revance Therapeutics. She is the founder and CEO of Skin Type Solutions Franchise Systems LLC. Write to her at dermnews@mdedge.com.